Baseline characteristics, disease activity, patient-reported outcomes (PROs) and safety in 465 patients with rheumatoid arthritis (RA) treated with filgotinib in Germany: Up to 18-month interim results from FILOSOPHY
Year: 2024
Type: conference-paper
Abstract: Introduction: A prospective, observational study (FILOSOPHY; NCT04871919) of filgotinib, a preferential Janus kinase 1 inhibitor for the treatment of RA, in a real-world setting is ongoing in Europe. We aimed to assess baseline characteristics, effectiveness, PROs and safety data for patients treated [for full text, please go to the a.m. URL]
DOI: 10.3205/24dgrh154
Authors: Andreica, Ioana, Bossaller, Lukas, Klopsch, Thilo, Bouzid, Ouafia, Debray, Thomas, Recke, Madita, Sieburg, Maren, Burmester, Gerd-Rüdiger
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6889869822
FWCI:
Cites:
Cited by:
Related to: